FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986670981> ?p ?o ?g. }

• W1986670981 endingPage "343" @default.
• W1986670981 startingPage "334" @default.
• W1986670981 abstract "Epirubicin was effective for the treatment of non-small cell lung carcinoma (NSCLC). This study compared the efficacy and safety of gemcitabine plus conventional-dose epirubicin (GE) with gemcitabine-cisplatin (GC) as first-line chemotherapy for stage IIIB/IV NSCLC and evaluated the predictive value of nuclear expression of excision repair cross-complementing group 1 (ERCC1) and topoisomerase IIalpha (TopoIIalpha) on treatment outcome.Patients were randomized to GE (gemcitabine, 1000mg/m(2) on days 1, 8, and 15 and epirubicin, 70mg/m(2) on day 15) or GC (gemcitabine, 1000mg/m(2) on days 1, 8, and 15 and cisplatin, 80mg/m(2) on day 15). Treatment cycles were repeated every 4 weeks. Immunohistochemical study of ERCC1 and TopoIIalpha was done for patients with available tumor specimens.The response rate was 31.0% (95% CI 16.4-45.5%) for GC (n=41) and 37.2.0% (95% CI 22.2-52.3%) for GE (n=39). No significant differences in median time-to-treatment-failure (TTF) (GC, 6.1 months; GE, 6.2 months) or overall survival (GC, 13.2 months; GE, 21.5 months) were found between the two arms. Grade 3/4 neutropenia and febrile neutropenia were more common in GE. However, delay of protocol treatment due to leukopenia was similar between the two arms. Patients with expression of both ERCC1 and TopoIIalpha had a significantly shorter TTF (median 2.4 months, 95% CI 0.7-4.1 months) than other patients (median 8.8 months, 95% CI 5.8-11.8 months) (p=0.04).GE regimen is effective and well-tolerated for NSCLC patients. Expression of both ERCC1 and TopoIIalpha may be associated with poor response to chemotherapy." @default.
• W1986670981 created "2016-06-24" @default.
• W1986670981 creator A5004080279 @default.
• W1986670981 creator A5006754529 @default.
• W1986670981 creator A5007140901 @default.
• W1986670981 creator A5017953971 @default.
• W1986670981 creator A5035504048 @default.
• W1986670981 creator A5043008228 @default.
• W1986670981 creator A5044689121 @default.
• W1986670981 creator A5048965137 @default.
• W1986670981 creator A5049887825 @default.
• W1986670981 creator A5074026718 @default.
• W1986670981 date "2008-12-01" @default.
• W1986670981 modified "2023-10-17" @default.
• W1986670981 title "Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma—A randomized phase II trial" @default.
• W1986670981 cites W1555396697 @default.
• W1986670981 cites W1802949207 @default.
• W1986670981 cites W1927667739 @default.
• W1986670981 cites W1965390776 @default.
• W1986670981 cites W1980585781 @default.
• W1986670981 cites W1982860886 @default.
• W1986670981 cites W1997479094 @default.
• W1986670981 cites W2004718750 @default.
• W1986670981 cites W2005395472 @default.
• W1986670981 cites W2005599761 @default.
• W1986670981 cites W2009599943 @default.
• W1986670981 cites W2018580664 @default.
• W1986670981 cites W2027059918 @default.
• W1986670981 cites W2027267113 @default.
• W1986670981 cites W2029504561 @default.
• W1986670981 cites W2030644627 @default.
• W1986670981 cites W2032332769 @default.
• W1986670981 cites W2036089394 @default.
• W1986670981 cites W2037408699 @default.
• W1986670981 cites W2047621538 @default.
• W1986670981 cites W2052848470 @default.
• W1986670981 cites W2061274521 @default.
• W1986670981 cites W2066783216 @default.
• W1986670981 cites W2068881045 @default.
• W1986670981 cites W2079709880 @default.
• W1986670981 cites W2083190627 @default.
• W1986670981 cites W2098645377 @default.
• W1986670981 cites W2103192876 @default.
• W1986670981 cites W2107183277 @default.
• W1986670981 cites W2110116826 @default.
• W1986670981 cites W2125540170 @default.
• W1986670981 cites W2125687910 @default.
• W1986670981 cites W2129447971 @default.
• W1986670981 cites W2135836212 @default.
• W1986670981 cites W2138297714 @default.
• W1986670981 cites W2145653040 @default.
• W1986670981 cites W2147703884 @default.
• W1986670981 cites W2148464027 @default.
• W1986670981 cites W2150358925 @default.
• W1986670981 cites W2151784729 @default.
• W1986670981 cites W2153477391 @default.
• W1986670981 cites W2154520658 @default.
• W1986670981 cites W2157187503 @default.
• W1986670981 cites W2164193849 @default.
• W1986670981 cites W2167805334 @default.
• W1986670981 cites W2240703358 @default.
• W1986670981 cites W2317310395 @default.
• W1986670981 cites W4251219890 @default.
• W1986670981 cites W4251309185 @default.
• W1986670981 cites W2589918366 @default.
• W1986670981 doi "https://doi.org/10.1016/j.lungcan.2008.03.010" @default.
• W1986670981 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18450322" @default.
• W1986670981 hasPublicationYear "2008" @default.
• W1986670981 type Work @default.
• W1986670981 sameAs 1986670981 @default.
• W1986670981 citedByCount "14" @default.
• W1986670981 countsByYear W19866709812012 @default.
• W1986670981 countsByYear W19866709812013 @default.
• W1986670981 countsByYear W19866709812014 @default.
• W1986670981 countsByYear W19866709812015 @default.
• W1986670981 countsByYear W19866709812016 @default.
• W1986670981 countsByYear W19866709812017 @default.
• W1986670981 crossrefType "journal-article" @default.
• W1986670981 hasAuthorship W1986670981A5004080279 @default.
• W1986670981 hasAuthorship W1986670981A5006754529 @default.
• W1986670981 hasAuthorship W1986670981A5007140901 @default.
• W1986670981 hasAuthorship W1986670981A5017953971 @default.
• W1986670981 hasAuthorship W1986670981A5035504048 @default.
• W1986670981 hasAuthorship W1986670981A5043008228 @default.
• W1986670981 hasAuthorship W1986670981A5044689121 @default.
• W1986670981 hasAuthorship W1986670981A5048965137 @default.
• W1986670981 hasAuthorship W1986670981A5049887825 @default.
• W1986670981 hasAuthorship W1986670981A5074026718 @default.
• W1986670981 hasConcept C126322002 @default.
• W1986670981 hasConcept C141071460 @default.
• W1986670981 hasConcept C143998085 @default.
• W1986670981 hasConcept C2776256026 @default.
• W1986670981 hasConcept C2776694085 @default.
• W1986670981 hasConcept C2776755627 @default.
• W1986670981 hasConcept C2777063308 @default.
• W1986670981 hasConcept C2778239845 @default.
• W1986670981 hasConcept C2778397455 @default.
• W1986670981 hasConcept C2778850193 @default.

• next